ONCO
Companies
NASDAQ
Onconetix Inc.
Health Care
$4.35
Price Chart
Overview
About ONCO
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Market Cap
$3.6M
Volume
345.1M
Avg. Volume
136.7M
P/E Ratio
-0.095529415
Dividend Yield
0.00%
Employees
7.0
Company Information
Latest News for ONCO
Risk & Correlation Analysis
Market Correlation
N/A
N/A
Volatility
N/A
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ONCO shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 26, 2025 (after market close)Other info last updated April 2, 2025